87 related articles for article (PubMed ID: 29502423)
1. Systemic Administration of siRNA with Anti-HB-EGF Antibody-Modified Lipid Nanoparticles for the Treatment of Triple-Negative Breast Cancer.
Okamoto A; Asai T; Hirai Y; Shimizu K; Koide H; Minamino T; Oku N
Mol Pharm; 2018 Apr; 15(4):1495-1504. PubMed ID: 29502423
[TBL] [Abstract][Full Text] [Related]
2. Targeted Dual pH-Sensitive Lipid ECO/siRNA Self-Assembly Nanoparticles Facilitate In Vivo Cytosolic sieIF4E Delivery and Overcome Paclitaxel Resistance in Breast Cancer Therapy.
Gujrati M; Vaidya AM; Mack M; Snyder D; Malamas A; Lu ZR
Adv Healthc Mater; 2016 Nov; 5(22):2882-2895. PubMed ID: 27723260
[TBL] [Abstract][Full Text] [Related]
3. Intraperitoneal siRNA Nanoparticles for Augmentation of Gemcitabine Efficacy in the Treatment of Pancreatic Cancer.
Tang S; Hang Y; Ding L; Tang W; Yu A; Zhang C; Sil D; Xie Y; Oupický D
Mol Pharm; 2021 Dec; 18(12):4448-4458. PubMed ID: 34699242
[TBL] [Abstract][Full Text] [Related]
4. Targeted delivery of polo-like kinase 1 siRNA nanoparticles using an EGFR-PEG bispecific antibody inhibits proliferation of high-risk neuroblastoma.
Logan A; Howard CB; Huda P; Kimpton K; Ma Z; Thurecht KJ; McCarroll JA; Moles E; Kavallaris M
J Control Release; 2024 Mar; 367():806-820. PubMed ID: 38341177
[TBL] [Abstract][Full Text] [Related]
5. Antibody h-R3-dendrimer mediated siRNA has excellent endosomal escape and tumor targeted delivery ability, and represents efficient siPLK1 silencing and inhibition of cell proliferation, migration and invasion.
Li J; Liu J; Li S; Hao Y; Chen L; Zhang X
Oncotarget; 2016 Mar; 7(12):13782-96. PubMed ID: 26883109
[TBL] [Abstract][Full Text] [Related]
6. Development of amino acid-modified biodegradable lipid nanoparticles for siRNA delivery.
Patel P; Fetse J; Lin CY; Guo Y; Hasan MR; Nakhjiri M; Zhao Z; Jain A; Cheng K
Acta Biomater; 2022 Dec; 154():374-384. PubMed ID: 36191773
[TBL] [Abstract][Full Text] [Related]
7. Multiple suppressing small interfering RNA for cancer treatment-Application to triple-negative breast cancer.
Lee J; Bang JH; Ryu YC; Hwang BH
Biotechnol J; 2023 Nov; 18(11):e2300060. PubMed ID: 37478121
[TBL] [Abstract][Full Text] [Related]
8. ICAM-1-Targeted, Lcn2 siRNA-Encapsulating Liposomes are Potent Anti-angiogenic Agents for Triple Negative Breast Cancer.
Guo P; Yang J; Jia D; Moses MA; Auguste DT
Theranostics; 2016; 6(1):1-13. PubMed ID: 26722369
[TBL] [Abstract][Full Text] [Related]
9. Mono-arginine Cholesterol-based Small Lipid Nanoparticles as a Systemic siRNA Delivery Platform for Effective Cancer Therapy.
Lee J; Saw PE; Gujrati V; Lee Y; Kim H; Kang S; Choi M; Kim JI; Jon S
Theranostics; 2016; 6(2):192-203. PubMed ID: 26877778
[TBL] [Abstract][Full Text] [Related]
10. Targeted gene silencing of CCL2 inhibits triple negative breast cancer progression by blocking cancer stem cell renewal and M2 macrophage recruitment.
Fang WB; Yao M; Brummer G; Acevedo D; Alhakamy N; Berkland C; Cheng N
Oncotarget; 2016 Aug; 7(31):49349-49367. PubMed ID: 27283985
[TBL] [Abstract][Full Text] [Related]
11. Hypoxia-responsive ionizable liposome delivery siRNA for glioma therapy.
Liu HM; Zhang YF; Xie YD; Cai YF; Li BY; Li W; Zeng LY; Li YL; Yu RT
Int J Nanomedicine; 2017; 12():1065-1083. PubMed ID: 28223799
[TBL] [Abstract][Full Text] [Related]
12. Persistent Targeting DNA Nanocarrier Made of 3D Structural Unit Assembled from Only One Basic Multi-Palindromic Oligonucleotide for Precise Gene Cancer Therapy.
Wu J; Zheng X; Lin W; Chen L; Wu ZS
Adv Healthc Mater; 2024 Apr; 13(11):e2303865. PubMed ID: 38289018
[TBL] [Abstract][Full Text] [Related]
13. Psoralen-loaded polymeric lipid nanoparticles combined with paclitaxel for the treatment of triple-negative breast cancer.
Liu F; Li L; Lan M; Zou T; Kong Z; Cai T; Wu X; Cai Y
Nanomedicine (Lond); 2021 Nov; 16(27):2411-2430. PubMed ID: 34749510
[No Abstract] [Full Text] [Related]
14. Technologies for investigating the physiological barriers to efficient lipid nanoparticle-siRNA delivery.
Shi B; Abrams M
J Histochem Cytochem; 2013 Jun; 61(6):407-20. PubMed ID: 23504369
[TBL] [Abstract][Full Text] [Related]
15. Novel synthesized ionizable lipid for LNP-mediated P2X7siRNA to inhibit migration and induce apoptosis of breast cancer cells.
Kiaie SH; Zangi AR; Sheibani M; Hemmati S; Baradaran B; Valizadeh H
Purinergic Signal; 2024 Mar; ():. PubMed ID: 38436880
[TBL] [Abstract][Full Text] [Related]
16. Frizzled7 Antibody-Functionalized Nanoshells Enable Multivalent Binding for Wnt Signaling Inhibition in Triple Negative Breast Cancer Cells.
Riley RS; Day ES
Small; 2017 Jul; 13(26):. PubMed ID: 28544579
[TBL] [Abstract][Full Text] [Related]
17. Precise targeting of POLR2A as a therapeutic strategy for human triple negative breast cancer.
Xu J; Liu Y; Li Y; Wang H; Stewart S; Van der Jeught K; Agarwal P; Zhang Y; Liu S; Zhao G; Wan J; Lu X; He X
Nat Nanotechnol; 2019 Apr; 14(4):388-397. PubMed ID: 30804480
[TBL] [Abstract][Full Text] [Related]
18. Precision treatment of viral pneumonia through macrophage-targeted lipid nanoparticle delivery.
Zhao G; Xue L; Geisler HC; Xu J; Li X; Mitchell MJ; Vaughan AE
Proc Natl Acad Sci U S A; 2024 Feb; 121(7):e2314747121. PubMed ID: 38315853
[TBL] [Abstract][Full Text] [Related]
19. Novel Iodine nanoparticles target vascular mimicry in intracerebral triple negative human MDA-MB-231 breast tumors.
Ridwan SM; Hainfeld JF; Ross V; Stanishevskiy Y; Smilowitz HM
Sci Rep; 2021 Jan; 11(1):1203. PubMed ID: 33441981
[TBL] [Abstract][Full Text] [Related]
20. Plasmid DNA ionisable lipid nanoparticles as non-inert carriers and potent immune activators for cancer immunotherapy.
Qin Y; Rouatbi N; Wang JT; Baker R; Spicer J; Walters AA; Al-Jamal KT
J Control Release; 2024 May; 369():251-265. PubMed ID: 38493950
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
